宝藿苷Ⅰ与索拉非尼的药物组合物及其在制备抗肝癌药物中的应用
By combining cyproheptadine I with sorafenib, the Ras/MAPK pathway is synergistically inhibited and metabolic reprogramming is induced, thus solving the problems of drug resistance and adverse reactions of sorafenib in the treatment of hepatocellular carcinoma and achieving a more effective treatment effect for liver cancer.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CHENZHOU NO 1 PEOPLES HOSPITAL
- Filing Date
- 2026-05-25
- Publication Date
- 2026-07-17
AI Technical Summary
Sorafenib's efficacy in treating hepatocellular carcinoma (HCC) is limited by drug resistance and adverse reactions, and existing studies have not explored the mechanism of combination therapy between cyproheptadine I and sorafenib.
A pharmaceutical composition of cyproheptadine I and sorafenib was provided. Through high-throughput screening and multi-omics analysis, it was confirmed that the synergistic inhibition of the Ras/MAPK pathway and the induction of metabolic reprogramming were used to prepare an anti-liver cancer drug.
It significantly inhibits the proliferation, migration, and invasion of liver cancer cells, reverses the EMT process, reduces the toxic side effects of sorafenib, improves patient compliance, and provides a multi-target combination strategy to overcome drug resistance.
Smart Images
Figure CN122398835A_ABST